Law and research could add up to profitable niche drugs
SIR -In response to your Editorial "A changing drug supply" (Nature 445, 460; 2007), W. Ross Tracey points out in Correspondence that niche drugs may be just as expensive as blockbuster drugs to bring to the market, but a pharmaceutical company's revenue from them is likely to be only a fraction of what it can earn from selling blockbusters ("Niche drugs aren't a cheap alternative to blockbusters" Nature 445, 818; 2007). This is not necessarily so, in my opinion. Why do so few women speak at science meetings?
SIR -Mary Ann Holmes and Suzanne O'Connell comment on the lack of women in the academic ranks in your Recruiters article "Leaks in the pipeline" (Nature 446, 346; 2007). In the same issue, advertisements for two Nature conferences illustrate part of the problem -the poor representation of women speakers at scientific meetings.
The Nature conference "Oncogenes and human cancer: the next 25 years" features 36 speakers, of whom four are women. The "Days of molecular medicine: emerging technologies and cancer biology" conference, co-sponsored by Nature Medicine, features 19 speakers, of whom two are women. There are many accomplished women scientists in the areas covered by these meetings. There is no obvious reason why the number of women speakers should be so low.
The representation of women speakers at many meetings remains dismally poor and thus may contribute to the lack of success of women in academia.
However, this is a problem that could be easily remedied, if more attention were paid by organizers and the agencies that provide funding for meetings to the issue of whether qualified female speakers have been missed. Ever since this idea was recommended by the Nuffield Council on Bioethics, I have been probing scientists for their response to it. Almost without exception, those I have approached have recognized its potential and support the idea verbally. However, they have consistently been reticent about providing any written endorsement.
The first, but, in my opinion, least likely, reason for this behaviour could be apathy, because this sensible, moderate and pragmatic proposal does not arouse the same emotions as the 'animal research' debate itself.
Second, the polarized nature of this topic may foster the fear that publicly supporting any measure to improve animal welfare will be perceived as a defection by other scientists.
Third, there may be an unwillingness to admit what some would see as a weakening of stance -the thin end of a wedge that threatens to phase out animal research altogether. Although my personal desire is that this would indeed be the outcome, the evidence speaks otherwise. Despite the best efforts of animal-welfare advocates since the 3Rs concept was first introduced, 'replacements' have become established only when they are of scientific benefitso it seems unreasonable that efforts to encourage them should be viewed as a threat to progress.
Finally, there is resistance to going against the grain. If a single high-impact journal were to take a unilateral decision to implement this proposal and embrace the 3Rs as integral and essential elements of good experimental design, I believe that other editors and scientists everywhere would be happy to follow.
